The universal chimeric antigen receptor (UniCAR) second-generation 2-component platform includes a CD28 costimulatory domain, a first component, which is a CAR that recognizes a targeting module included in the second component, which confers specificity against the tumor antigen of choice. Here, CD28 is linked to neoplasm.